文献速递膀胱癌与上尿路尿路上皮癌

上尿路尿路上皮癌内镜下保肾手术的长期肿瘤学与功能结局:大型单中心队列

Endoscopic Kidney-sparing Surgery for Upper Tract Urothelial Carcinoma: Long-term Oncological and Functional Outcomes from a Large Single-center Cohort.
PubMed 文献 · Eur Urol Oncol · 2026-07-03

该单中心回顾性队列纳入254例接受内镜下保肾手术(eKSS)的上尿路尿路上皮癌(UTUC)患者,按EAU风险分层。中位随访67个月,5年和7年复发率分别为49%和55%,高危组转为根治性肾输尿管切除术、转移进展和癌特异性死亡风险均显著高于低危组,而CKD≥IIIB发生率无显著组间差异。

要点

  • eKSS后5年和7年复发率分别为49%和55%,风险组间无显著差异。
  • 高危组转为RNU、转移进展和癌特异性死亡风险显著高于低危组。
  • eKSS后5年CKD≥IIIB发生率为15%,风险组间无显著差异。

核心结论

  • eKSS的长期数据为临床咨询提供真实世界基准,高危疾病与更高的RNU转换、转移进展和CSM风险相关,支持EAU风险分层的预后价值及风险适配的延长内镜监测。

研究设计与样本

  • 回顾性分析前瞻性维护的单中心队列(1996年8月至2024年9月),排除诊断性输尿管镜后直接行根治性肾输尿管切除术、缺失索引病理或缺乏肿瘤随访者,最终纳入254例eKSS治疗患者。

主要发现

  • 中位年龄71岁(IQR 62-77),男性占74%,低危占46%。
  • 幸存者中位随访67个月(IQR 24-131),5年和7年复发率分别为49%(95% CI 42-57%)和55%(95% CI 47-63%),风险组间无统计学显著差异(sHR 0.74,95% CI 0.51-1.08,p=0.12)。
  • 高危组较低危组:RNU风险更高(sHR 2.30,95% CI 1.34-3.94;7年风险35% vs 13%);转移进展7年发生率17% vs 5.0%(sHR 2.79,95% CI 1.10-7.08);CSM 7年发生率23% vs 11%(95% CI 9.2-23%;sHR 2.24,95% CI 1.10-4.55)。
  • eGFR中位下降-9 mL/min/1.73 m2(IQR -11至-2);5年CKD≥IIIB发生率15%(95% CI 8-21%),风险组间无统计学显著差异(sHR 1.63,95% CI 0.72-3.70;p=0.2)。

关键数值与推荐

  • 按EAU标准将患者分为低危和高危,并接受标准化监测,包括4-6周二次输尿管镜检查和长期输尿管镜随访。

临床怎么用

  • eKSS适用于UTUC保肾治疗,应依据EAU风险分层进行预后咨询和风险适配的延长内镜监测。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Long-term benchmark data on endoscopic kidney-sparing surgery (eKSS) for upper tract urothelial carcinoma (UTUC) remain limited. OBJECTIVE: To report long-term oncological and functional outcomes from a large single-center cohort using contemporary risk stratification. DESIGN, SETTING, AND PARTICIPANTS: We retrospectively analyzed a prospectively maintained cohort (August 1996-September 2024). After excluding patients with upfront radical nephroureterectomy (RNU) after diagnostic ureteroscopy, missing index pathology, or lacking oncologic follow-up, 254 eKSS-treated patients were included. INTERVENTION: Endoscopic kidney-sparing surgery, with patients classified as low- (LR) or high-risk (HR) per EAU criteria and undergoing standardized surveillance including second-look ureteroscopy at 4-6 weeks and long-term ureteroscopic follow-up. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: Outcomes included UTUC recurrence, RNU, metastases, cancer-specific mortality (CSM), and chronic kidney disease (CKD) ≥IIIB. Cumulative incidence functions and Fine-Gray competing-risk regression were used. RESULTS AND LIMITATIONS: Median age was 71 years (IQR 62-77); 74% were male and 46% were LR. After a median follow-up of 67 months (IQR 24-131) for survivors, 5- and 7-yr recurrence incidence was 49% (95% CI 42-57%) and 55% (95% CI 47-63%), without statistically significant differences between risk groups (subdistribution hazard ratio [sHR] 0.74, 95% CI 0.51-1.08, p=0.12). High-risk disease was associated with higher hazards of RNU (sHR 2.30, 95% CI 1.34-3.94; 7-yr risk 35% vs. 13%), metastatic progression (7-yr incidence 17% vs. 5.0%; sHR 2.79, 95% CI 1.10-7.08), and CSM (7-yr incidence 23% vs. 11%, 95% CI 9.2-23%; sHR 2.24, 95% CI 1.10-4.55) compared to LR patients. Median eGFR decline was -9 mL/min/1.73 m2 (IQR -11 - -2); 5-yr CKD ≥IIIB incidence was 15% (95% CI 8-21%), with no risk-group statistically significant differences (sHR 1.63, 95% CI 0.72-3.70; p = 0.2). CONCLUSIONS: These long-term data provide real-world benchmarks for clinicians counseling patients undergoing eKSS. High-risk disease is associated with higher hazards of RNU conversion, metastatic progression, and CSM, reinforcing the prognostic value of EAU risk stratification and the need for risk-adapted, prolonged endoscopic surveillance after eKSS.

来源:Eur Urol Oncol,查看原文。版权归原作者所有。

引用

  1. Scilipoti P, Zorzi F, Ippolita Jannello LM, et al. Endoscopic Kidney-sparing Surgery for Upper Tract Urothelial Carcinoma: Long-term Oncological and Functional Outcomes from a Large Single-center Cohort. Eur Urol Oncol. 2026. PMID: 42399121. doi:10.1016/j.euo.2026.05.011

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。